Stockscreener 앱 받기
58.88
0.79%
-0.47
시간 외 거래:
58.88
전일 마감가:
$59.35
열려 있는:
$59.7
하루 거래량:
937.43K
Relative Volume:
0.70
시가총액:
$5.62B
수익:
$7.50M
순이익/손실:
$-345.91M
주가수익비율:
-13.50
EPS:
-4.3602
순현금흐름:
$-280.51M
1주 성능:
+2.33%
1개월 성능:
+6.61%
6개월 성능:
+40.53%
1년 성능:
+78.26%
1일 변동 폭
$58.35
$59.70
1주일 범위
$57.44
$59.99
52주 변동 폭
$28.19
$63.95
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
명칭
Xenon Pharmaceuticals Inc
전화
(604) 484-3300
주소
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
58.88 | 5.66B | 7.50M | -345.91M | -280.51M | -4.3602 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-01-04 | 개시 | Citigroup | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 개시 | Goldman | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-10-19 | 개시 | Raymond James | Outperform |
| 2022-08-29 | 개시 | BofA Securities | Buy |
| 2022-07-21 | 개시 | JP Morgan | Overweight |
| 2021-10-28 | 개시 | RBC Capital Mkts | Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-07-21 | 개시 | Needham | Buy |
| 2020-06-01 | 재개 | Jefferies | Buy |
| 2020-03-25 | 개시 | Wedbush | Outperform |
| 2020-01-08 | 개시 | William Blair | Outperform |
| 2019-09-20 | 개시 | Guggenheim | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2017-03-13 | 개시 | Jefferies | Buy |
| 2016-10-21 | 개시 | Stifel | Buy |
| 2016-09-26 | 개시 | Guggenheim | Buy |
| 2016-04-14 | 재확인 | Jefferies | Buy |
| 2015-10-30 | 재개 | Jefferies | Buy |
| 2014-12-02 | 개시 | Canaccord Genuity | Buy |
모두보기
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Xenon to Present at Upcoming Investor Conferences - Yahoo Finance
Xenon Expands 2025 Inducement Equity Incentive Plan - The Globe and Mail
Xenon Pharmaceuticals Amends 2025 Inducement Equity Incentive Plan for Nasdaq Compliance and Employee Attraction 10 - Minichart
Xenon Pharmaceuticals (XENE) boosts 2025 inducement equity plan share reserve - Stock Titan
Certain Restricted Stock Units of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Certain Stock Options of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Certain Common Shares of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Published on: 2026-04-09 12:46:57 - baoquankhu1.vn
Xenon Pharmaceuticals to present azetukalner epilepsy data at AAN By Investing.com - Investing.com Australia
Xenon Pharmaceuticals to present azetukalner epilepsy data at AAN - Investing.com
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting - Bitget
Xenon brings 48-month epilepsy drug data and Phase 3 results to AAN - Stock Titan
Xenon Pharmaceuticals (NASDAQ:XENE) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - AOL.com
XENE SEC FilingsXenon Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan
Aberdeen Group plc Increases Stock Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (XENE) climbs 31.7% as epilepsy treatment moves forward - MSN
XENE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
XENE PE Ratio & Valuation, Is XENE Overvalued - Intellectia AI
Xenon Pharmaceuticals Inc.Common Shares (NQ: XENE - The Chronicle-Journal
XENE Should I Buy - Intellectia AI
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals stock soars 20% in 3 months: Here's why - MSN
How Positive Phase 3 Azetukalner Results and Upsized Financing Could Reframe Xenon Pharmaceuticals (XENE) Investors - Sahm
Assenagon Asset Management S.A. Invests $5.34 Million in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Assessing Xenon Pharmaceuticals (XENE) Valuation After Positive Phase 3 Results And US$750 Million Capital Raise - Sahm
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - The Motley Fool
Xenon Pharmaceuticals (XENE) price target increased by 41.64% to 80.01 - MSN
Wolfe Research initiates coverage of Xenon Pharmaceuticals (XENE) with outperform recommendation - MSN
Crude oil rises around 4%; Xenon Pharmaceuticals shares surge - MSN
(XENE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Published on: 2026-03-22 04:08:37 - baoquankhu1.vn
Xenon Pharmaceuticals rallies after pivotal data shows major drop in monthly seizures - MSN
Xenon Pharmaceuticals stock faces pipeline scrutiny amid biotech sector volatility - AD HOC NEWS
JPMorgan Chase & Co. Purchases 142,452 Shares of Xenon Pharmaceuticals Inc. $XENE - marketbeat.com
Xenon Pharmaceuticals Shares Jump 20% Over Three Months: The Reasons Explained - Bitget
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why - The Globe and Mail
Investors Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc (XENE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):